The Monitoring Messenger: Mobile Patient Monitoring for the Pediatric Intensive Care Unit
|ClinicalTrials.gov Identifier: NCT01612091|
Recruitment Status : Withdrawn (Replaced with updated protocol as H16-02361)
First Posted : June 5, 2012
Last Update Posted : October 26, 2017
|Condition or disease||Intervention/treatment|
|Medical Device User-Computer Interface Critical Care Physiologic Monitoring||Device: Monitoring Messenger Device: Traditional tools|
There are a limited number of nurses, respiratory therapists and physicians in an ICU at a given time. To make decisions and plan therapies, these clinicians need to observe, assimilate and interpret a vast array of information originating from various devices located on the bedsides of multiple patients. Several shortcomings in existing technology limit their abilities: a) the fixed location of monitoring devices at the bedside; b) information overload from a multitude of devices, each with its own display; c) the lack of integration and interaction between these devices; d) the use of visually cumbersome displays, which were historically created for monitoring during anesthesia but never optimized for users in the ICU; and e) lack of context specific information (such as historical trends) to support patient data interpretation and clinical decision making.
This project proposes to address these challenges in ICU monitoring by developing a unified, portable, and intelligent device: the Monitoring Messenger. By integrating information from multiple monitoring devices, mechanical ventilators, infusion pumps and clinical information systems on a mobile device (tablet PC or smart phone); the Monitoring Messenger will allow nurses, respiratory therapists and physicians on or off-site, to continuously monitor critically ill patients, thereby increasing patient safety.
The proposed experiment will have two parts: Part I - Participatory design and Part II - Simulation Experiment.
In Part I - Participatory Design. Participatory design an inter-professional team of nurses, physicians, designers, engineers, and human factors experts will follow a user-centered design process to obtain the system requirements, and obtain feedback during the rapid prototyping phase of prototype development. While we expect the resulting prototype to be easy to use, support decision making, improve awareness of the patient's condition by health care providers and reduce mental workload, this methodology is not hypothesis driven.
Part II - Simulation Experiment. In simulated ICU scenarios, the critical care physicians, nurses, and respiratory therapists will prioritize the care of critically ill patients. We expect them to do so more accurately with the use of Monitoring Messenger than with their regular tool (monitors, paper records etc). A potential outcome would be a decrease in mental workload as well as an increase in situational awareness.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||The Monitoring Messenger: Mobile Patient Monitoring for the Pediatric Intensive Care Unit|
|Study Start Date :||November 2013|
|Estimated Primary Completion Date :||January 2017|
|Estimated Study Completion Date :||January 2017|
|Experimental: Monitoring Messenger||
Device: Monitoring Messenger
Monitoring Messenger prototype device
Active Comparator: Control
Traditional tools (monitors, paper records)
Device: Traditional tools
Paper based records, screenshots of monitors and therapy devices
- Accuracy of priority assignment in triaging task [ Time Frame: Up to 1 hour ]Accuracy will be measured by matching of the participants triage priority ranking with the previously defined expert ranking.
- Requirements for design of the mobile device [ Time Frame: Up to 2 hours ]Information requirements for tasks, task frequencies, perceived challenges and potential suggestions to improve their current work environment using a mobile monitoring and messaging device
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01612091
|Canada, British Columbia|
|BC Children's Hospital|
|Vancouver, British Columbia, Canada, V6H 3V4|
|Principal Investigator:||Mark Ansermino, MBBCh, FRCPC||The University of British Columbia|